CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A

As of June 30, 2026, CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A carries a market capitalization of 9.71B, placing it among publicly traded companies globally. Its enterprise value stands at 8.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A has 1.76B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A maintains a current ratio of 5.04, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A recorded 2.37M in income tax expense.

As of the close on October 23, 2026, CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A's stock has declined approximately 23.24% over the past 52 weeks. The 50-day moving average sits at 6.26, while the 200-day moving average is 6.72.

As of June 30, 2026, CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A holds 1.65B in cash and equivalents against 6.80M in total debt, resulting in a net debt position of -1.43B. Total book value stands at 2.09B, with working capital of 1.51B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A's most recent stock split took place on June 23, 2016 with a 10:11 split ratio.